drugset / Trial / NCT05122572
RT-01 Monotherapy and in Combination With Nivolumab in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, open-lable study to determine the safety, tolerability and preliminary efficacy of oncolytic virus injection (RT-01) combined with or without immune checkpoint inhibitors (Nivolumab) in the treatment of patients with advanced solid tumors.
Timeline
- Start
- 2021-11-01
- Primary completion
- 2022-06-01
- Completion
- 2023-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | — | — |
| Subject | RT-01 | Other / unclassified | — | Intravenous |